Johannes Wesling Klinikum, Minden, Germany Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2016
NCT02953301
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Johannes Wesling Klinikum Minden - Minden, Germany

Active Ingredients

Drugs in Phase 2 Trials (2)

atezolizumab (Tecentriq) (1 trial)

resminostat (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphoma (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Mycoses (Phase 2)

Mycosis Fungoides (Phase 2)

Sezary Syndrome (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2